► Adenoid cystic carcinoma of Bartholin's gland is extremely rare, and only 80 cases have been reported in the international literature. ► We have presented a case in which a favorable outcome was achieved by chemoradiotherapy with CPT-11. ► This is the first report, to our knowledge, on chemoradiotherapy with CPT-11 for adenoid cystic carcinoma of Bartholin's gland.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862213 | PMC |
| http://dx.doi.org/10.1016/j.gynor.2012.12.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unexpected presentation: metastatic adenoid cystic carcinoma (AdCC) of the breast masquerading as a large cystic-solid renal mass.
BMJ Case Rep
January 2025
Department of Urology, Austin Hospital, East Melbourne, Victoria, Australia.
Adenoid cystic carcinoma (AdCC) of the breast is a rare histological subtype of breast cancer, which usually has a low propensity for metastasis and is associated with a good prognosis. AdCC metastasis to the kidney is rare, with only 29 cases reported in the literature. We report a case of a woman in her 60s with multiple right-sided large cystic-solid renal lesions after a recent diagnosis of marginal zone B-cell lymphoma.
View Article and Find Full Text PDFArticle Synopsis
- Adenoid cystic carcinomas (AdCC) of salivary gland origin are primarily defined by the presence of specific gene fusions, notably MYB::NFIB and MYBL1::NFIB, with sinonasal AdCC being particularly aggressive and lacking effective treatments.
- Researchers conducted an extensive analysis of 88 sinonasal AdCC cases using various techniques like NGS and FISH to identify gene fusions and mutations, finding that the majority harbored canonical fusions while some had noncanonical ones, with a few tumors showing no fusions at all.
- Mutational analysis revealed that about 68% of AdCCs tested (21 out of 31) had mutations in key oncogenes, highlighting potential areas for targeted
Retraction of: CCNA2 and KIF23 are molecular targets for the prognosis of adenoid cystic carcinoma.
Aging (Albany NY)
December 2024
Department of Otolaryngology, Head and Neck Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050030, P.R. China.
Outcomes in Adenoid Cystic Carcinoma: A 14-Year Analysis.
Cureus
December 2024
Oncology: Radiation Oncology, Tawam Hospital, Al Ain, ARE.
Background Adenoid cystic carcinoma (ACC) is a rare malignancy characterized by slow progression, local recurrence, and distant metastases. This study aims to evaluate the demographic patterns, clinical presentations, outcomes, and survival trends of patients with ACC. Methods A retrospective analysis of 14 patients diagnosed with ACC from 2010 to 2024 at a tertiary cancer center in the United Arab Emirates was conducted.
View Article and Find Full Text PDFAdenoid cystic carcinoma of the breast, from diagnosis to management: a case report.
J Med Case Rep
January 2025
Department of Pathology and Laboratories, University Hospital Fundación Santa Fe de Bogotá, Bogotá, DC, Colombia.
Background: Adenoid cystic carcinoma of the breast is a rare subtype, constituting less than 3.5% of primary breast carcinomas. Despite being categorized as a type of triple-negative breast cancer, it generally has a favorable prognosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!